Concept:
Invasive Pulmonary Aspergillosis (IPA) is a major life-threatening opportunistic fungal infection in severely immunocompromised and prolonged neutropenic pediatric oncology patients.
Prompt recognition via imaging findings (CT chest halo sign) and biomarkers (serum galactomannan assay) followed by immediate targeted antifungal therapy is crucial for survival.
Explanation:
• Aspergillus species (most commonly Aspergillus fumigatus) are angioinvasive molds that cause pulmonary tissue infarction and necrosis.
• The classic CT chest finding is the "halo sign", which represents an area of ground-glass attenuation surrounding a pulmonary nodule or consolidation, corresponding to alveolar hemorrhage surrounding ischemic fungal necrosis.
• Galactomannan is a polysaccharide cell wall component released during active hyphal growth of Aspergillus, serving as a validated diagnostic serological biomarker.
• Voriconazole, an extended-spectrum triazole, is recommended by the Infectious Diseases Society of America (IDSA) and European guidelines as the first-line drug of choice for targeted treatment of invasive aspergillosis.
• Fluconazole is entirely inactive against Aspergillus species (it has activity limited mainly to Candida and Cryptococcus).
• Caspofungin and other echinocandins are considered second-line or salvage agents, not the primary treatment of choice for invasive pulmonary aspergillosis.
Final Answer:
The first-line drug of choice for the treatment of invasive pulmonary aspergillosis is voriconazole.